MedTrace Logo

Comparison of Ultrasound-Guided Infraclavicular Block and Ultrasound-Guided Axillary Block

NCT01761175 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 224

Last updated 2017-08-04

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the rate of complete sensory block at 30 minutes following ultrasound-guided single injection infraclavicular block and ultrasound-guided double injection axillary block. The investigators research hypothesis is that both blocks will show comparable rates of complete sensory block at 30 minutes.

Conditions

  • Anesthesia

Interventions

PROCEDURE

Ultrasound-guided infraclavicular block

Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.

PROCEDURE

Ultrasound-guided axillary block

Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.

Sponsors & Collaborators

  • CHU de Quebec-Universite Laval

    lead OTHER

Principal Investigators

  • Ariane Boivin, MD · CHU de Québec

  • Marie-Josée Nadeau, MD · CHU de Québec

  • Nicolas Dion, MD · CHU de Québec

  • Simon Lévesque, MD · CHU de Québec

  • Pierre C. Nicole, MD · CHU de Québec

  • Alexis F. Turgeon, MD, Msc · CHU de Québec

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-02-28
Completion
2013-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01761175 on ClinicalTrials.gov